Intranasal administration of asenapine and pharmaceutical compositions therefor
OwnerJosephine Elisabeth Maria van der Sterren, Dennie J.M. van den Heuvelinventors
Life of this patent
Estimating the term…
Abstract
Asenapine or a pharmaceutically acceptable salt thereof can be administered intranasally, typically via an intranasal dosage formulation having a water-containing liquid carrier.
Claims20
An intranasal dosage formulation, which comprises:
- asenapine or a pharmaceutically acceptable salt thereof and a water-containing liquid carrier, wherein the formulation is adapted for intranasal administration.
An intranasal dosage formulation, which comprises:
- asenapine or a pharmaceutically acceptable salt thereof in a concentration of 10 to 100 mg/ml;
- a liquid carrier comprising water and a polyol;
- an isotonizing agent;
- optionally a bacteriostatic agent;
- and
- optionally a thickener and/or a humectant.
A method, which comprises administering via intranasal exposure an effective amount of asenapine or a pharmaceutically acceptable salt thereof to a patient in need thereof.
The method according to claim 18, wherein said patient is suffering from schizophrenia and said amount of asenapine is an anti-schizophrenia effective amount.
Dependencies are inferred from the claim text.